Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-α2a compared with sunitinib

2010-10-12

British Journal of Cancer , Volume 103 - Issue 8 p. 1309- 1310

Additional Metadata
Persistent URL	doi.org/10.1038/sj.bjc.6605887, hdl.handle.net/1765/53225
Journal	British Journal of Cancer
Organisation	Erasmus School of Health Policy & Management (ESHPM)
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Mickisch, G. H. J., Escudier, B., Walzer, S., & Nuijten, M. (2010). Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-α2a compared with sunitinib. British Journal of Cancer, 103(8), 1309–1310. doi:10.1038/sj.bjc.6605887

Publication